Navigation Links
Enzyme affects hypertension by controlling salt levels in body

An enzyme known to cause hypertension increases blood pressure by activating tiny pores, or channels, in kidney cells that allow increased levels of sodium to be reabsorbed into the blood, researchers at UT Southwestern Medical Center have found. The findings shed light on the underlying mechanisms that cause hypertension, and may also help explain why patients with hypertension linked to salt intake often need to take potassium supplements in order to keep their high blood pressure in check.

The study will appear in an upcoming issue of the Proceedings of the National Academy of Sciences.

"This is a classic example of how basic research could lead to better understanding of human diseases and potentially to new therapeutic methods," said Dr. Bing-E Xu, assistant professor of pharmacology at UT Southwestern and lead author of the study.

The enzyme WNK1 is known to cause a form of hypertension, abbreviated PHA II, but until now the method by which it affected blood pressure was unclear. By studying animal and human cells in culture, UT Southwestern researchers determined that WNK1 interacts with and activates another enzyme, SGK1, which is well known to lead to the activation of sodium ion channels in kidney cells.

"The kidney plays a very important role in controlling blood pressure by controlling how much sodium gets reabsorbed back into the kidney and the blood," said Dr. Chou-Long Huang, associate professor of internal medicine at UT Southwestern and co-senior author of the study. "Sodium comes into the kidney cell through these channels and is then returned to blood circulation through another sodium transporter," he said. "The sodium channel critically governs how much sodium gets reabsorbed."

Normally, the kidney filters and reabsorbs about 99 percent of sodium from the blood and returns it to the body, excreting 1 percent through urine, said Dr. Huang, a nephrologist.

However, if salt ingestion remains the same a nd the kidneys reabsorb 99.9 percent of salt, too much salt returns to the blood, increasing blood volume and leading to hypertension. If less than 99 percent is absorbed, low blood pressure develops.

Dr. Huang said that not everyone who eats too much salt ends up with hypertension, but some population groups, such as African-Americans, are more prone to develop salt-sensitive high blood pressure, suggesting that genetic factors may play a role in the disease.

One extension of the current work may lead to a better understanding of hypertension that is induced by low potassium intake. Previous studies have shown that diuretics, a class of drugs commonly used to control hypertension, also cause potassium wasting, or low potassium levels, in patients.

"Studies have shown that if you are taking diuretics and let your potassium level fall, the diuretics are not as effective," Dr. Huang said. "But if you take diuretics and you supplement with potassium, you can lower blood pressure more effectively." Dr. Huang and his research group currently are conducting studies to determine whether low potassium intake increases WNK1 activity, leading to hypertension.

The WNK1 enzyme was first identified and cloned in 2000 by UT Southwestern researchers led by Dr. Melanie Cobb, co-senior author on the PNAS paper and dean of UT Southwestern Graduate School of Biomedical Sciences. After cloning the enzyme, Dr. Cobb's research group examined what proteins might be regulated by WNK1, and found that SGK1 was one of those proteins. Because he works on ion channels, including sodium channels, Dr. Huang joined efforts with Dr. Cobb to study how WNK1 regulates sodium channels.

"We have been working on WNK1 for several years now and these findings are unexpected from initial studies," said Dr. Cobb. "What is particularly satisfying and exciting is the ease with which we could establish such a collaboration at UT Southwestern to study the physiological and medical implications of our findings."

Other UT Southwestern researchers involved in the study were Steve Stippec, pharmacology research associate; Dr. Ahmed Lazrak, instructor of internal medicine; Dr. Xin-Ji Li, research associate in internal medicine; Dr. Byung-Hoon Lee, postdoctoral researcher in pharmacology; and Dr. Bernardo Ortega, postdoctoral researcher in internal medicine. Former postdoctoral researchers Dr. Po-Yin Chu and Dr. Jessie M. English also contributed.


'"/>

Source:UT Southwestern Medical Center


Related biology news :

1. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
2. Novel Enzyme Shows Potential As An Anti-HIV Target
3. Enzyme allows B cells to resist death, leading to leukemia
4. Enzyme shown to help protect genomic stability
5. Measuring Enzymes At End Of Cancer Pathway Predicts Outcome Of Tarceva, Taxol
6. Enzymes newly discovered role may make it target for arthritis treatment
7. Promiscuous Catalytic Activity Possessed by Novel Enzyme Structure
8. Gene Bridges And Covalys To Develop Restriction-Enzyme-Free SNAP-tag Gene Fusion Kits
9. Newly Discovered Role for Heart Response Enzyme May Yield Better Heart Failure Therapy
10. Enzyme inhibitors block replication of SARS virus
11. Enzyme crystal structure reveals unexpected genome repair functions
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
Breaking Biology Technology: